TANAFFOS (Respiration)

TANAFFOS (Respiration)

New Insights into Pulmonary Arterial Hypertension Treatment with Non-Coding RNAs: What is the Best Option, microRNAs or Small-Interfering RNAs?

Document Type : Letter to Editor

Authors
Hannaneh Yousefi-Koma 1
Babak Sharif-Kashani 1
Abdolreza Mohammadnia 2
Mahdi Ahmadinia 1
Shadi Shafaghi 1
1 Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Chronic Respiratory Diseases Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract
Pulmonary arterial hypertension is a devastating disease that can lead to other serious comorbidities. Heart failure is a major problem in patients with pulmonary arterial hypertension. It usually begins with right-sided heart failure, but in severe or uncontrolled cases, it can progress to left-sided heart failure. Currently, available treatment options do not have desirable effects. Therefore, considering a new treatment strategy is a cardiology priority. Non-coding RNAs, including small interfering RNA and microRNA, are valuable treatment options to study. Several non-coding RNAs have been studied and even approved for treatment in other hard-to-treat diseases. However, deciding which to choose can be complex. That is because these non-coding RNAs can have multiple interaction processes. Therefore, a thorough understanding of pulmonary arterial hypertension's pathological pathways and our target non-coding RNA interaction pathways is crucial. Here, we discuss the potential benefits and harms of these options in treating patients with pulmonary arterial hypertension.
Keywords
Pulmonary arterial hypertension
Non-coding RNA
Small interfering RNA
MicroRNA
Pulmonary hypertension
Subjects
TANAFFOS (Respiration)
Volume 24, Issue 1
Winter 2025
Pages 1-5